Considerations in the Management of HER2+ Breast Cancer MEDSTAT_JS MEDSTAT_CSS

Considerations in the Management of HER2+ Breast Cancer

Aditya Bardia, MD, MPH, is joined by Adam Brufsky, MD, PhD, Sara Hurvitz, MD, and Hope Rugo, MD, for a discussion on recent FDA approvals, guidance on therapeutic sequencing, and the future of HER2+ breast cancer.

Video 1: Treatment Sequencing

The panel reviews some of the newest players in the HER2+ breast cancer treatment landscape and discusses how to incorporate these agents into a patient’s treatment plan.

Up Next

Video 1: Treatment Sequencing
Video 2: Early-Stage HER2+ Breast Cancer Regimens
Video 3: The Future of HER2+ Treatment

MEDSTAT_LATEST_NEWS_WIDGET

About the Panel

Dr. Bardia Photo

Aditya, Bardia M.D. – Moderator

  • Attending Physician,
  • Department of Medical Oncology,
  • Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Dr. Hurvitz Photo

Sara A. Hurvitz, MD,

  • Associate Professor,
  • Department of Hematology-Oncology,
  • University of California, Los Angeles
Dr. Brufsky Photo

Adam M. Brufsky, MD, PhD,

  • Professor,
  • Department of Medicine, Division of Hematology-Oncology,
  • University of Pittsburgh School of Medicine
  • Pittsburgh, Pennsylvania
Dr. Veluswamy Photo

Hope S. Rugo, MD,

  • Professor,
  • Division of Hematology and Oncology,
  • University of California, San Francisco Medical Center
Disclosures

Dr. Bardia has disclosed that he has conculted for Biotheranostics; Daiichi Sankyo; AstraZeneca; Genentech; Immunomedics; Eli Lilly and Company; Novartis; Pfizer; Puma Biotechnology; Merck; Philips; Radius Health; Sanofi; Spectrum Pharmaceuticals; Foundation Medicine; Taiho Pharmaceutical

Dr. Hurvitz has previously received research grants from: Ambrx; Amgen Inc.; Bayer HealthCare Pharmaceuticals; Daiichi Sankyo, Inc.; Dignitana AB; Eli Lilly and Company; Genentech, Inc.; GlaxoSmithKline; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Pfizer Inc; Pieris Pharmaceuticals Inc; Puma Biotechnology; Radius Health; Roche Pharma; sanofi-aventis; Seattle Genetics, Inc.

Dr. Brufsky has disclosed no relevant financial relationships

Dr. Rugo has been a consultant for Samsung and Puma; and has received research grants from: Pfizer; Merck; Novartis; Eli Lilly and Company; Genentech; OBI; Odonate; Daiichi Sankyo; Seattle Genetics; Eisai; MacroGenics; Sermonix; Immunomedics